The first volunteer in a new clinical trial is not just testing a treatment. They are testing a hypothesis about where hearing loss truly resides. For decades, the standard response to age-related hearing trouble has been an amplifier in the ear. Parley Neurotech, a clinical-stage spinout from the University of Colorado Anschutz, is betting the real problem is often in the brain, and that fixing it requires a combination of pharmacology and precise acoustics.
The company’s therapy, called LOOT, is a first-in-class candidate for age-related central auditory processing disorder (CAPD). Often described as "cocktail party syndrome," CAPD makes it difficult to parse speech in noisy environments, a deficit that hearing aids cannot fully address. Parley’s approach combines a repurposed, FDA-approved drug intended to support neural repair with a proprietary sound-stimulation protocol engineered to target specific central auditory pathways [CU Anschutz Physiology, 2024]. The company recently enrolled its first participant in a double-blind Phase I/IIa trial after receiving FDA approval, marking a critical transition from academic research to clinical validation [CU Innovations, 2024].
A Wedge Into Brain Health and Longevity
Parley’s initial target is adults over 40 who struggle to hear in noise, a population the company cites as one in three people over 40 and half of those over 65 [F6S, 2024]. The commercial ambition, however, extends beyond audiology. The company positions CAPD as the single largest modifiable risk factor for dementia, citing the Lancet Commission on dementia prevention [CU Anschutz Physiology, 2024]. This framing places Parley at the intersection of two massive, aging markets: hearing restoration and cognitive longevity. Success in the clinic could open doors not just to otologists but to neurologists and geriatricians focused on delaying cognitive decline.
The company’s foundation is deeply academic. The core science originated in the lab of co-founder and Chief Scientific Officer Achim Klug, a professor of physiology and biophysics at CU Anschutz [CU Anschutz Physiology, 2024]. CEO Sam Budoff, who holds a PhD in neuroscience from the same institution, moved from a postdoctoral role in Klug’s lab to commercialize the research [RocketReach, 2026]. This origin provides strong intellectual property, licensed from the university, but it also defines the company’s early, research-heavy stage [CU Innovations, 2024]. Public funding details are sparse, with support noted from the university’s SPARK CU Innovations translational program [F6S, 2024].
The Long Road of Neurotherapeutic Development
The path from a first patient to a marketed treatment is long, expensive, and fraught with risk. Parley is at the very beginning of that journey. The current Phase I/IIa trial, while a necessary milestone, is primarily designed to assess safety and early signals of efficacy. Demonstrating statistically significant and clinically meaningful improvement in hearing-in-noise tests will require larger, more costly Phase IIb and Phase III studies.
Competition in hearing therapeutics is also advancing, though often from a different angle. Companies like Frequency Therapeutics and Decibel Therapeutics have pursued regenerative approaches targeting the inner ear’s hair cells. Parley’s distinct bet is on the central auditory system, a less crowded but arguably more complex therapeutic frontier. The risks are not trivial.
- Clinical validation. The repurposed drug’s effect on auditory processing in humans, especially when paired with sound stimulation, remains unproven. Negative trial results would be a fundamental setback.
- Capital intensity. Neurotherapeutic trials are among the most expensive in biotech. The company’s undisclosed funding to date suggests a significant Series A round will be necessary to reach the next inflection point.
- Commercial pathway. Even with approval, educating physicians and patients on a new category of "brain hearing" treatment represents a substantial market development challenge.
The company’s near-term trajectory will be dictated by data. All eyes will be on the readout from the initial trial cohort, expected within the next 12-18 months. Positive results would provide the catalyst needed to attract larger life science investors and build the war chest for a pivotal study.
For the estimated millions of adults with age-related central auditory processing disorder, the current standard of care is largely adaptive, not restorative. It involves strategies like speechreading, auditory training exercises, and environmental modifications, often supplemented by hearing aids that amplify sound but do not repair the brain’s processing deficit. There is no FDA-approved pharmaceutical or device therapy that directly targets the neural circuits involved. Parley Neurotech’s bet is that its drug-and-sound protocol can change that, offering not just better hearing in a crowded room, but a potential lever to pull against cognitive decline.
Sources
- [CU Anschutz Physiology, 2024] Parley Neurotech | https://medschool.cuanschutz.edu/physiology/news/parley-neurotech
- [CU Innovations, 2024] A First-of-its-kind Treatment for Brain-Based Hearing Loss | https://news.cuanschutz.edu/cu-innovations/first-of-its-kind-treatment-for-brain-based-hearing-loss
- [F6S, 2024] Parley Neurotech | https://www.f6s.com/company/parley-neurotech
- [RocketReach, 2026] Sam Budoff Email & Phone Number | Parley Neurotech., Inc. Chief Executive Officer Contact Information | https://rocketreach.co/sam-budoff-email_857670153